Plain-English translation of NCT07109518 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called universal CD7 CAR-T cells () for patients with certain types of blood cancer that have stopped responding to standard chemotherapy. The treatment works by taking immune cells from your body, engineering them in a lab to recognize and attack cancer cells, and then infusing them back into you. Researchers want to find the safest and most effective dose of this medication.
For patients with relapsed or refractory acute myeloid leukemia and T-cell lymphoblastic leukemia, standard chemotherapy often stops working. This trial exists to test whether this new engineered cell therapy can offer hope to patients who have run out of other treatment options.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy drugs (fludarabine and cyclophosphamide) to prepare your body, followed by an infusion of the engineered CAR-T cells. The trial uses a "dose escalation" design, meaning early participants receive lower doses while doctors watch carefully for safety, and later participants may receive higher doses if the treatment is tolerated well. You would be closely monitored for side effects and response to the treatment throughout the study.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China